knowledge -WSS

knowledge

author：comprehensive 2025-08-28 08:40:31 - browse：32

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Medicare Advantage insurers face 0.2% cut to 2025 payments

entertainment

WSS

White House drug shortage group privately met with industry

TytoCare raises $49 million to build out AI

FTC sues over Novant Health acquisition of two N.C. hospitals

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Biden calls for immediate release of Niger's president amid apparent coup

Syphilis numbers in the United States reach record heights

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

In age of alternative facts, a scholarly course on calling out crap

Attacks on the drug industry will lead to fewer breakthroughs

Jerome Adams on the need for new antivirals for Covid

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Medical leaders decry Supreme Court decision on affirmative action

Attacks on the drug industry will lead to fewer breakthroughs

Heart attack and stroke risk calculators need revising

What the cancer research community can learn from the Covid response

focus

The drug industry sees a key ally in the Senate prevail

Philips to halt sales of sleep apnea machines in U.S.

FTC sues over Novant Health acquisition of two N.C. hospitals

Health Care Service Corp to buy Cigna Medicare Advantage plans

Investment in vaccine development is lagging, report finds

Health Care Service Corp to buy Cigna Medicare Advantage plans

hotspot

entertainment

entertainment

focus